Gelteq Launches Human and Veterinary Clinical Trials as Pharmaceutical Pipeline Expands Across Multiple Programs

Gelteq Limited's gel-based oral delivery platform is moving from preclinical concept toward active clinical testing, with a human trial scheduled to commence in Q3 2026 and a veterinary antiparasitic study already underway, a dual-track progression that will test whether the platform can satisfy FDA regulatory pathway requirements across two distinct approval frameworks simultaneously.

The Melbourne-based biotech, listed on NASDAQ as GELS, completed human clinical trial planning in the first half of 2026 and expects to initiate the study beginning July 1, 2026. The veterinary program targets an FDA application later this year for an antiparasitic candidate, with the global animal health market estimated at over US$78 billion. For formulation and regulatory teams tracking novel oral delivery technologies, the concurrent submissions represent an early stress test of the platform's adaptability across 21 CFR-governed approval routes.

Gelteq has also commenced a preclinical diabetes study, extending its pharmaceutical pipeline into a high-volume chronic-disease category where oral bioavailability of peptide-based compounds remains a persistent formulation challenge. In parallel, the company is developing stable oral formulations for peptides and complex biologics conventionally administered by injection, a class of compounds that includes GLP-1 receptor agonists and other injectable therapeutics where patient compliance with injection regimens is a documented clinical concern.

On the commercial side, Gelteq completed palatability trials with Kemin Industries, confirming canine acceptance and bitter-masking performance for functional ingredients. The company also manufactured commercial product for a new East Asian customer and established a Center of Excellence in Guangdong Province, China, providing manufacturing and development access within a major pharmaceutical supply ecosystem. A strategic debt financing of up to US$3.5 million with an institutional investor has been secured to fund clinical advancement and commercialization activities.

The human clinical trial initiation in Q3 2026 will be the first measurable indicator of whether Gelteq's formulation data translates into a viable FDA regulatory submission timeline.

Source: GlobeNewswire via Globe Newswire Industry News on Pharmaceuticals, June 17, 2026.